Ficonalkib clinical trials
Also written SY-3505 and CT-3505.
How each study uses ficonalkib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ficonalkib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Shouyao Holdings (Beijing) Co. LTD (4)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ficonalkib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNot yet recruitingPhase 3Shouyao Holdings (Beijing) Co. LTDNCT06254599Written as SY-3505 Capsules
- A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid TumorsRecruitingPhase 1Shouyao Holdings (Beijing) Co. LTDNCT06037317Written as SY-3505
- Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKIRecruitingPhase 2Shouyao Holdings (Beijing) Co. LTDNCT05869162Written as SY-3505
- Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung CancerStatus unknownPhase 1/2Shouyao Holdings (Beijing) Co. LTDNCT05257512Written as SY-3505
Codes
What other systems call ficonalkib · ClinicalTrials.gg INT015652
- UNII (FDA) 8EPZ3U4PSSFICONALKIBConfirmed FDA, Wikidata
- Wikidata Q140640985ficonalkibConfirmed FDA, Wikidata
- NCI Thesaurus C199050FiconalkibOne source FDA
- DrugBank DB18774One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8EPZ3U4PSS | FICONALKIB | Confirmed FDA, Wikidata |
| Wikidata | Q140640985 | ficonalkib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C199050 | Ficonalkib | One source FDA |
| DrugBank | DB18774 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.